Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Avita Medical ( (RCEL) ) has provided an announcement.
Avita Medical, Inc. recently amended and restated its bylaws to align with updates in applicable law concerning stockholder meetings and electronic notices. These changes are expected to impact the company’s governance practices and stakeholder engagement.
The most recent analyst rating on (RCEL) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Avita Medical stock, see the RCEL Stock Forecast page.
Spark’s Take on RCEL Stock
According to Spark, TipRanks’ AI Analyst, RCEL is a Neutral.
Avita Medical’s stock score reflects a blend of strong revenue growth and technical momentum, offset by severe profitability challenges and high financial leverage. While future revenue projections and product expansions are promising, underlying financial weaknesses and valuation concerns present significant risks.
To see Spark’s full report on RCEL stock, click here.
More about Avita Medical
Average Trading Volume: 233,194
Technical Sentiment Signal: Sell
Current Market Cap: $185.3M
Learn more about RCEL stock on TipRanks’ Stock Analysis page.